Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

Summary

The purpose of this Phase 2 study is to assess the pharmacokinetics (PK) and safety of RLYB212 in HPA-1b/b pregnant women at higher risk for HPA-1a alloimmunization and FNAIT.

Timeline

Start

2024-11-21

Primary completion

2025-10-01

Completion

2025-10-01

Outcome

Outcome not reported

Stopped: “This study was terminated early by the sponsor due to insufficient drug exposure to achieve the intended therapeutic effect.”

Drugs

Indications